07 September 2021 : Clinical Research
Clinical Observation of Prophylactic Extended-Field Intensity-Modulated Radiation Therapy with Synchronous Chemotherapy in Locally Advanced Cervical Cancer
Xue Huang1ABCDEFG, Mingming Fang2BCF, Lin Zhu1BCDF, Cheng Gu2ABG, Han Cui3BCDG, Chun Yang4ACDF, Yuxing Yang1ABDF*DOI: 10.12659/MSM.930457
Med Sci Monit 2021; 27:e930457
Table 1 The 2 groups were comparable in age, Karnofsky performance score (KPS), tumor size, pathological type, and clinical stage (P>0.05).
| Group | Extended-field group (n=17) | Pelvic-field group (n=17) | χ2 value | P value |
|---|---|---|---|---|
| Median age | 55 | 57 | ||
| Median KPS score | 80 | 80 | ||
| Tumor size | 0.23 (Fisher) | 0.6282 | ||
| <4cm | 2 (11.76%) | 3 (17.65%) | 1 | |
| ≥4cm | 15 (88.24%) | 14 (82.35%) | ||
| Pathological result | 0 (Fisher) | 1 | ||
| Non-squamous cell carcinoma | 1 (5.88%) | 1 (5.88%) | 1 | |
| Squamous cell carcinoma | 16 (94.12%) | 16 (94.12%) | ||
| Clinical stage | 3.31 (Fisher) | 0.6518 | ||
| IB | 1 (5.88%) | 0 (0.00%) | 0.8845 | |
| IIA | 1 (5.88%) | 1 (5.88%) | ||
| IIB | 8 (47.06%) | 10 (58.82%) | ||
| IIIA | 0 (0.00%) | 1 (5.88%) | ||
| IIIB | 6 (35.29%) | 5 (29.41%) | ||
| IVA | 1 (5.88%) | 0 (0.00%) |